From Smartphones to AI: ARM's Expanding Global Tech Influence
What sets ARM apart is its unmatched ability to deliver high performance with minimal power consumption, an increasingly critical requirement as the world becomes more connected and intelligent. From wearables to cloud data centers, AI workloads are proliferating across device categories, and Arm Holdings' flexible, energy-efficient architecture is being adopted to meet these next-generation demands.
Apple continues to rely heavily on Arm Holdings' architecture, using it as the backbone for its M-series chips and accelerating AI integration across its ecosystem. Qualcomm, a long-time partner, leverages Arm Holdings' designs in its Snapdragon processors to fuel AI-driven innovations in smartphones and automotive platforms. Samsung, too, embeds Arm technology in its mobile and consumer electronics devices while advancing AI and IoT capabilities through its Exynos chipsets.
The reliance on ARM by these tech leaders isn't just continuing — it's deepening. As Apple, Qualcomm and Samsung scale up their AI ambitions and broaden their IoT strategies, Arm Holdings remains central to enabling this transformation through its scalable power efficiency. The company's commitment to optimizing its architecture for machine learning and edge computing further strengthens its alignment with the strategic needs of its top clients.
In this light, Arm Holdings is no longer just a key player in mobile chip design — it is fast becoming an essential infrastructure layer powering the AI and IoT future for Apple, Qualcomm and Samsung. Its growing role cements its position as a critical enabler in the broader technology ecosystem.
ARM's Price Performance, Valuation & Estimates
The stock has climbed 41% in the past three months, underperforming the industry 's 45% growth.
From a valuation standpoint, ARM trades at a forward price-to-sales ratio of 30.92, well above the industry's 8.64. It carries a Value Score of F.
The Zacks Consensus Estimate for ARM's earnings has remained unchanged over the past 30 days.
ARM stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QUALCOMM Incorporated (QCOM): Free Stock Analysis Report
Apple Inc. (AAPL): Free Stock Analysis Report
ARM Holdings PLC Sponsored ADR (ARM): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
3 hours ago
- CTV News
The ‘godfather of AI' reveals the only way humanity can survive superintelligent AI
Geoffrey Hinton, known as the 'godfather of AI,' fears the technology he helped build could wipe out humanity — and 'tech bros' are taking the wrong approach to stop it. Hinton, a Nobel Prize-winning computer scientist and a former Google executive, has warned in the past that there is a 10% to 20% chance that AI wipes out humans. On Tuesday, he expressed doubts about how tech companies are trying to ensure humans remain 'dominant' over 'submissive' AI systems. 'That's not going to work. They're going to be much smarter than us. They're going to have all sorts of ways to get around that,' Hinton said at Ai4, an industry conference in Las Vegas. In the future, Hinton warned, AI systems might be able to control humans just as easily as an adult can bribe 3-year-old with candy. This year has already seen examples of AI systems willing to deceive, cheat and steal to achieve their goals. For example, to avoid being replaced, one AI model tried to blackmail an engineer about an affair it learned about in an email. Instead of forcing AI to submit to humans, Hinton presented an intriguing solution: building 'maternal instincts' into AI models, so 'they really care about people' even once the technology becomes more powerful and smarter than humans. AI systems 'will very quickly develop two subgoals, if they're smart: One is to stay alive… (and) the other subgoal is to get more control,' Hinton said. 'There is good reason to believe that any kind of agentic AI will try to stay alive.' That's why it is important to foster a sense of compassion for people, Hinton argued. At the conference, he noted that mothers have instincts and social pressure to care for their babies. 'The right model is the only model we have of a more intelligent thing being controlled by a less intelligent thing, which is a mother being controlled by her baby,' Hinton said. 'The only good outcome' Hinton said it's not clear to him exactly how that can be done technically but stressed it's critical researchers work on it. 'That's the only good outcome. If it's not going to parent me, it's going to replace me,' he said. 'These super-intelligent caring AI mothers, most of them won't want to get rid of the maternal instinct because they don't want us to die.' Hinton is known for his pioneering work on neural networks, which helped pave the way to today's AI boom. In 2023, he stepped down from Google and started speaking out about the dangers of AI. Not everyone is on board with Hinton's mother AI approach. Fei-Fei Li, known as the 'godmother of AI' for her pioneering work in the field, told CNN on Wednesday that she respectfully disagrees with Hinton, her longtime friend. 'I think that's the wrong way to frame it,' Li, the co-founder and CEO of spatial intelligence startup World Labs, said during a fireside chat at Ai4. Instead, Li is calling for 'human-centered AI that preserves human dignity and human agency.' 'It's our responsibility at every single level to create and use technology in the most responsible way. And at no moment, not a single human should be asked or should choose to let go of our dignity,' Li said. 'Just because a tool is powerful, as a mother, as an educator and as an inventor, I really believe this is the core of how AI should be centered.' Emmett Shear, who briefly served as interim CEO of ChatGPT owner OpenAI, said he's not surprised that some AI systems have tried to blackmail humans or bypass shutdown orders. 'This keeps happening. This is not going to stop happening,' Shear, the CEO of AI alignment startup Softmax, said at the Ai4 conference. 'AIs today are relatively weak, but they're getting stronger really fast.' Shear said that rather than trying to instill human values into AI systems, a smarter approach would be to forge collaborative relationships between humans and AI. AI is accelerating faster than expected Many experts believe AIs will achieve superintelligence, also known as artificial general intelligence, or AGI, in the coming years. Hinton said he used to think it could take 30 years to 50 years to achieve AGI but now sees this moment coming sooner. 'A reasonable bet is sometime between five and 20 years,' he said. While Hinton remains concerned about what could go wrong with AI, he is hopeful the technology will pave the way to medical breakthroughs. 'We're going to see radical new drugs. We are going to get much better cancer treatment than the present,' he said. For instance, he said AI will help doctors comb through and correlate the vast amounts of data produced by MRI and CT scans. However, Hinton does not believe AI will help humans achieve immortality. 'I don't believe we'll live forever,' Hinton said. 'I think living forever would be a big mistake. Do you want the world run by 200-year-old white men?' Asked if there's anything he would have done differently in his career if he knew how fast AI would accelerate, Hinton said he regrets solely focusing on getting AI to work. 'I wish I'd thought about safety issues, too,' he said. By Matt Egan, CNN
Globe and Mail
3 hours ago
- Globe and Mail
Orthopedic Devices Market Poised for 4.78% CAGR Growth Through 2030: FDA Approvals, Breakthrough Device Designation and AI-Enabled Devices Reshape the Market
DelveInsight projects the orthopedic devices market to grow from USD 44.09B in 2023 to USD 57.79B by 2030 at a 4.78% CAGR, driven by rising musculoskeletal disorders and innovation. Key players include Stryker, Zimmer Biomet, Johnson & Johnson, Medtronic, Maxx Orthopedics, Hyalex Orthopaedics, and OrthoPreserve. FDA approvals, AI-enabled devices, and breakthrough technologies like OSCAR PRO, AccelStim, and UNID systems propel market expansion. DelveInsight's ' Orthopedic Devices - Global Market Insights, Competitive Landscape, and Market Forecast - 2030 ' report delivers a comprehensive analysis of the Orthopedic Devices market globally. Key Takeaways Market size projection: As per DelveInsight's analysis, the total market size of Orthopedic Devices globally is expected to surge from USD 44.09 billion in 2023 to USD 57.79 billion by 2030. Patient population data: The report provides the total musculoskeletal disease potential pool, highlighting that 1.71 billion people suffer from conditions such as osteoarthritis, osteoporosis, and rheumatoid arthritis globally, with 528 million osteoarthritis and 18 million rheumatoid arthritis cases in 2019, plus ~300K people living with spinal cord injuries. Key orthopedic device companies: Leading orthopedic device companies, such as Stryker Corporation, Zimmer Biomet, Johnson & Johnson, and Medtronic PLC Pipeline assets: Some of the key orthopedic device innovations in the pipeline include the OSCAR PRO ultrasonic arthroplasty revision system, AccelStim Bone Growth Stimulator, AxSOS Ankle Fusion System, Insignia Hip stem, and AI-enabled UNID spinal fusion devices. In August 2025, the FDA approved the SetPoint System, a neuroimmune modulation device for treating adults with moderately to severely active rheumatoid arthritis. In June 2025, Maxx Orthopedics received FDA 510(k) clearance for their Freedom® Total Knee System Titanium Tibial Base Plate. This approval introduces a new material option, transitioning from CoCrMo to Wrought Titanium-6Aluminium-4Vanadium ELI Alloy (Ti6Al4V ELI) for the tibial base plate component. In May 2025, Hyalex Orthopaedics secured FDA approval of its supplemental Investigational Device Exemption (IDE) application for the Freestyle Knee Implant. In March 2025, Johnson & Johnson MedTech showcased major advances at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting. Building on their momentum from the previous year's 18 FDA 510(k) clearances and 45 global product launches, the company introduced cutting-edge implants, advanced techniques, and data-driven technologies across joint reconstruction, trauma, extremities, and spine specialties. January 2025: OrthoPreserve received Breakthrough Device Designation and enrolled in the FDA TAP program for its Defender meniscus replacement implant. Discover recent advancements in the Orthopedic Devices landscape @ Orthopedic Devices Recent Developments. Orthopedic Devices Market Dynamics The global orthopedic devices market reached USD 44.09 billion in 2023 and is expanding at a compound annual growth rate (CAGR) of 4.78%, projected to attain USD 57.79 billion by 2030. This growth reflects both demographic pressures, an aging population with 54.1 million U.S. residents aged 65 or older as of 2019, and the rising incidence of bone and joint disorders. Musculoskeletal conditions are the leading contributors to disability worldwide, driving substantial demand for implants, supports, and related devices. Orthopedic devices market drivers include the increasing prevalence of osteoarthritis (528 million cases) and osteoporosis, occupational and non-occupational injuries, and technological innovation in implant materials and design. Innovations such as biocompatible titanium constructs and AI-integrated hardware are elevating clinical outcomes and reducing complication rates. For instance, ultrasonic arthroplasty tools like OSCAR PRO facilitate minimally invasive revisions, while AccelStim enhances fracture healing through targeted bone stimulation. The advances in biomechanics, materials science, and regenerative engineering underpin device performance. Titanium interbody cages, porous polymer composites, and smart sensors are enabling load-sharing implants with real-time monitoring. Mechanistically, bone growth stimulators exploit electromagnetic or ultrasonic energy to upregulate osteoblast activity and accelerate fusion. The orthopedic devices innovation and development is robust, with numerous devices in various trial phases. OrthoPreserve's Defender meniscus replacement is in breakthrough designation pathways, and Medtronic's UNID system illustrates the integration of AI in device-guided spinal fusion. Concurrently, Stryker and Zimmer Biomet are conducting post-market surveillance studies to refine long-term safety profiles. The orthopedic devices competitive landscape features diversified strategies: major players invest in in-licensing and partnerships to expand portfolios, while mid-sized innovators focus on niche applications such as ankle and wrist arthrodesis. Strategic M&A activity is anticipated as companies seek to consolidate capabilities in biologics-enabled devices. The orthopedic devices market barriers include regulatory hurdles for novel biomaterials, reimbursement constraints, and potential competition from non-implant therapies (e.g., biologics, cell therapy). However, opportunities abound in emerging markets, tele-enabled surgery, and personalized implant design via 3D printing. The future outlook projects continued growth driven by demographic trends, rising healthcare expenditure, and sustained R&D investment in next-generation orthopedic solutions. Download the Orthopedic Devices Market report to understand which factors are driving the therapeutic market @ Orthopedic Devices Market Trends. Orthopedic Devices Potential Patient Pool Musculoskeletal disorders impact 1.71 billion individuals globally, with 528 million suffering from osteoarthritis and 18 million affected by rheumatoid arthritis as of 2019. Spinal cord injuries afflict approximately 296,000 patients worldwide, with 17,900 new cases annually. DelveInsight's epidemiology segmentation reveals that osteoarthritis accounts for the largest share of years lived with disability, followed by rheumatoid arthritis. The total orthopedic devices eligible patient pools encompass those requiring surgical implants or supportive orthoses, with treated cases driven by healthcare access and device availability. Geographic analysis indicates North America leads market adoption, followed by Europe and Asia-Pacific, where aging demographics and expanding surgical capacity fuel device uptake. Forecasting through 2030 anticipates rising incident cases and an expanding treated cohort as minimally invasive and outpatient surgical centers proliferate. Discover evolving trends in the Orthopedic Devices patient pool forecasts @ Orthopedic Devices Patient Pool Analysis. Key Orthopedic Devices Companies and Competitive Landscape The orthopedic devices sector is anchored by established players and dynamic innovators. Current treatment options range from prophylactic supports (braces, orthoses) to complex implants (total joint prostheses, spinal fusion systems). Stryker Corporation leads with its Insignia Hip stem and AxSOS Ankle Fusion System, leveraging titanium design and updated screw arrays to improve fusion rates. Zimmer Biomet's portfolio includes knee and shoulder implants, while Johnson & Johnson focuses on advanced soft-tissue fixation devices. Medtronic's UNID rods and screws incorporate AI algorithms to optimize spinal alignment intraoperatively. Orthopedic devices development activity features OrthoPreserve's Defender meniscus replacement entering pivotal trials under FDA Breakthrough Device designation and Orthofix's AccelStim in post-approval studies. Key partnerships include licensing agreements for biomaterial coatings and co-development of sensor-enabled implants. Market positioning emphasizes value-based outcomes, with companies forging payor contracts that reward reduced revision rates. Recent milestones encompass FDA clearances (AccelStim May 2022, UNID June 2021), AAOS product launches (Insignia March 2022), and strategic collaborations in 3D-printed implant manufacturing. Commercial arrangements involve joint ventures in emerging markets to enhance distribution networks. Collectively, these efforts define a competitive environment focused on enhancing patient outcomes, expanding indications, and driving long-term growth in the orthopedic devices landscape. Delve deeper into the major and specialised companies in the Orthopedic Devices market @ Orthopedic Devices Competitive Landscape. Conclusion The orthopedic devices market is poised for sustained expansion through 2030, driven by demographic imperatives, technological innovation, and a diversified competitive field. Strategic collaborations, regulatory breakthroughs, and evolving clinical practices will shape the future, ensuring that next-generation implants and support devices meet the growing global demand for improved musculoskeletal health. Table of Contents 1. Orthopedic Devices Market Report Introduction 2. Orthopedic Devices Market Executive Summary 3. Competitive Landscape 4. Regulatory Analysis 5. Orthopedic Devices Market Key Factors Analysis 6. Orthopedic Devices Market Porter's Five Forces Analysis 7. Orthopedic Devices Market Assessment 8. Orthopedic Devices Market Company and Product Profiles 9. KOL Views 10. Project Approach 11. About DelveInsight 12. Disclaimer & Contact Us About DelveInsight DelveInsight is a leading business consulting and market research company focused on the healthcare and life sciences sectors, providing comprehensive market intelligence, competitive landscape analysis, and strategic insights to support decision-making across the pharmaceutical industry. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Globe and Mail
4 hours ago
- Globe and Mail
Up 15% in 3 Months, Is Solana a Buy Right Now With $1,000?
Key Points Solana's price has been trending upward recently. It's gaining ground against Ethereum, continuing the prior trend. It'll need to keep building up its case for institutional adoption to proceed. 10 stocks we like better than Solana › Solana 's (CRYPTO: SOL) price has climbed by around 15% since late April, moving from about $146 to roughly $167 as I write this. The move is hardly breathtaking. Still, it prompts a pair of bigger questions. Namely, does an extra $1,000 of your portfolio belong allocated to this coin before the next leg up? And does it have what it takes to continue gaining in value for at least the next few years? Let's address both of these questions at once. This is a platform that's hitting its stride and fitting the market The story of Solana is one of an increasingly tight fit between its product, -- another way of saying its blockchain -- and what the market is looking for in terms of chain features. Solana's calling cards are its speed and cheapness. Over the last week, it averaged 2.2 million daily active wallet addresses and about 98 million daily transactions, all of which it accomplished while keeping transaction fees near fractions of a cent and its average transaction times within a second or two. Those figures tower over every major rival, especially incumbents like Ethereum, and the disparity explains why developers who are making consumer-scale decentralized apps (dApps) keep flocking to the chain. The upshot of these stellar performance features is that big money in the traditional financial sector is noticing. Faster settlement times and lower collateral demands are the bait for institutions, and fee savings are the hook. In late May, digital assets company R3 struck a deal with the Solana Foundation so its partnered financial institutions, most of which are big banks, can issue and trade tokenized stocks and bonds on the chain. The partnership vaults Solana into pole position for a slice of an asset tokenization market that could be worth as much as $16 trillion by 2030, according to estimates developed by Boston Consulting Group (BCG). Speed also resonates with two of crypto's newest darlings, the artificial intelligence (AI) segment, and decentralized physical infrastructure networks (DePIN). In July, the Neural AI gaming platform picked Solana for its creator-focused launchpad, citing sub-second confirmations as critical for real-time game logic. Other AI projects are flocking to the chain under the rationale that AI agents will be cheaper to operate when they don't need to hold as much of the chain's native token in their wallet to perform transactions compared to elsewhere. On the DePIN front, Solana-based wireless, compute, and mapping protocols have generated more than $3 million in on-chain revenue this year after setting a monthly record in June. Faster transaction times matter for accessing physical infrastructure apps because, for example, it'd be very frustrating if you had to wait for more than a moment or two to pay for access to a cafe's wifi network using a cryptocurrency. None of this traction is accidental. High throughput attracts developers, they ship apps that attract users, users attract capital seeking a return on investment in on-chain projects, and then swelling usage of the chain justifies even more ambitious upgrades to its throughput to keep the cycle going. You could still lose some of your $1,000 If your portfolio is big enough, taking on $1,000 of Solana isn't going to make or break it, but it's still important to appreciate the risks of an investment before diving in. In the past, most recently in February 2024, Solana has suffered headline-grabbing outages of its network. Those have been anomalies, and there is no indication that they will occur again, yet on a long enough timescale, they could. If the chain displays instability too frequently, which, once again, does not look probable even though it's possible, institutional investors could get spooked and look for other solutions. Separately, regulatory risk looms if U.S. government agencies shift their views on public-chain settlement of transactions, or their views on how tokenized assets must be handled. Solana's compliance feature set is far from vestigial, but it hasn't yet had a real stress test either. There will likely need to be more tech development within that space, which implies a risk of getting it wrong. Competition is also fierce. Ethereum's layer-2 (L2) roll-ups are cheaper every quarter, and emerging layer-1s (L1s) chase the same AI and DePIN segments as Solana, even if they're starting from a vastly smaller capital base. It isn't likely that any of those competitors will supplant Solana entirely, but at least somewhat hampering the growth of its market share in their focus segments is all but assured. Still, if Solana secures a meaningful share of asset tokenization, maintains its AI and DePIN leadership, and avoids catastrophic technical stumbles, today's price could look tiny in five years. For most investors, this argues in favor of a dollar-cost averaging strategy rather than a single lump-sum plunge. In other words, treat SOL like a high-volatility growth stock that's highly unpredictable from day-to-day, yet rewarding over the years if the thesis holds. Should you invest $1,000 in Solana right now? Before you buy stock in Solana, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Solana wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
